Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Last trade$3.55
Day change-$0.15 (-4.05%)
Day range$3.49 – $3.90
Volume214,715
Market cap$104M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$104.45M
Price / earnings
—
Price / book
3.24×
Price / sales
1.52×
EV / sales
1.57×
EV / EBITDA
77.56×
Profitability
Earnings per share
-$0.18
Return on assets
-4.91%
Return on equity
-15.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.81×
Current ratio
1.48×
Quick ratio
1.34×
Cash ratio
0.42×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.55M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DERM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$18.93M
$17.84M
$15.96M
$16.07M
$17.03M
$15.01M
$13.14M
$12.62M
Cost of revenue
$5.88M
$6.14M
$6.22M
$5.44M
$5.76M
$4.94M
$4.79M
$4.68M
Gross profit
$13.04M
$11.7M
$9.74M
$10.63M
$11.27M
$10.07M
$8.35M
$7.94M
Selling, general and administrative
$12.59M
$10.89M
$10.11M
$9.86M
$12.05M
$11.88M
$10.57M
$10.06M
Research and development
$51K
$54K
$0
$154K
$287K
$0
$39K
$218K
Total operating expenses
$13.61M
$11.91M
$11.24M
$11.08M
$13.41M
$12.95M
$11.67M
$6.71M
Operating income
-$572K
-$215K
-$1.49M
-$456K
-$2.14M
-$2.88M
-$3.32M
$1.23M
Interest expense
-$919K
-$906K
-$892K
-$933K
-$937K
-$937K
-$891K
-$831K
Income before taxes
-$1.32M
-$297K
-$2.23M
-$1.25M
-$2.32M
-$3.74M
-$4.07M
$1.58M
Income taxes
$0
$15K
$0
$0
$0
$60K
$0
$61K
Net income
-$1.32M
-$312K
-$2.23M
-$1.25M
-$2.32M
-$3.8M
-$4.07M
$1.52M
Net income attributable to common shareholders
-$1.32M
-$312K
-$2.23M
-$1.25M
-$2.32M
-$3.8M
-$4.07M
$1.52M
EBITDA
$397K
$754K
-$366K
$609K
-$1.07M
-$1.81M
-$2.26M
$2.22M
Basic earnings per share
-$0.05
-$0.01
-$0.08
-$0.05
-$0.09
-$0.16
-$0.18
$0.07
Diluted earnings per share
-$0.05
-$0.01
-$0.08
-$0.05
-$0.09
-$0.16
-$0.18
$0.07
Recent news
Company coverage with links to the original publishers.
Journey Medical reported Q3 2026 revenue of $18.97 million, up 7.6% year-over-year but missing the consensus estimate of $20.54 million by 7.66%. EPS of -$0.05 beat expectations of -$0.03. Key product revenues showed mixed results: Accutane slightly missed estimates, EmrosiTM significantly exceeded expectations with 84.4% YoY growth, while Qbrexza declined 24.1% year-over-year. The stock has a Zacks Rank #4 (Sell) rating.
Journey Medical Corporation reported a Q3 loss of $0.05 per share, missing consensus estimates of $0.03 loss, with revenues of $18.97 million falling 7.66% short of expectations. The company has underperformed the S&P 500 by 53.7% year-to-date and received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
Ocular Therapeutix (OCUL) reported a quarterly loss of $0.42 per share, missing the consensus estimate of $0.36, and posted revenues of $12.87 million, below the expected $13.78 million. The stock has declined 45.7% year-to-date and carries a Zacks Rank #3 (Hold) rating. The company is expected to post a loss of $0.37 per share next quarter with $13.78 million in revenues.
VAXART (VXRT) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.31 loss by 77.42%, though revenues of $10.62 million fell significantly from $72.41 million year-ago. The stock has outperformed the S&P 500 by 3.2% year-to-date. With a Zacks Rank #3 (Hold) rating, the company is expected to perform in line with the market, though the Medical-Drugs industry ranks in the top 41% of sectors.
Journey Medical Corporation (DERM) is expected to report a quarterly loss of $0.03 per share for Q3 2026, representing a 66.7% improvement year-over-year, with revenues expected at $20.54 million, up 16.5%. However, the consensus EPS estimate has been revised 140% lower over the last 30 days, and the stock carries a Zacks Rank #4 with a negative Earnings ESP of -166.67%, making it unlikely to beat earnings expectations. The company has beaten consensus estimates only once in the last four quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.